Each receptor pulls a different lever: GLP-1 curbs appetite and slows gastric emptying, GIP sharpens insulin secretion and may support lipid metabolism, and glucagon-receptor activation raises energy expenditure and drives fat oxidation [5] [8]
These glucagon-like peptide (GLP-1) receptor agonists mimic naturally occurring gastrointestinal hormones to help suppress appetite and enhance insulin secretion from the pancreas, one of the reasons these medications were first approved for treatment of type 2 diabetes
In addition, a recent study indicates that close to 530 million adult population suffers from diabetes globally
9-13 For women with history of depression, however, high depressive symptom scores are not limited to the perimenopause, but are reported across reproductive stages
Expected Weight Loss Results Clinical trials showing 14.9% average weight loss over 68 weeks used semaglutide at 2.4 mg weekly
Beyond Medication: The Complete Protocol Medication alone isn't the full answer
